Editing GlucoSet

{{DISPLAYTITLE:GlucoSet}}
{{Infobox company
| name = GlucoSet AS
| org_number = 997780922
| founded = 2011-12-19
| employees = 13
| address = Norway
| industry = 74.990 – Other professional/scientific/technical activities
| website = https://www.glucoset.com
| nht_category = Startup
| description = GlucoSet develops a minimally invasive glucose sensor for ICU (intensive care unit) patients. The sensor accesses through an indwelling arterial catheter without disrupting its current use, requiring no new catheters and displacing no other equipment. Targets the challenge of accurate, continuous glucose monitoring in critically ill patients, where current methods are inadequate.
| notes = 13 employees. Founded 2011 — one of the older NHT members. No disclosed revenue or funding. ICU glucose monitoring is a significant unmet need.
| related_companies = [[Ably Medical]], [[BabySensor]], [[Cardiaccs]], [[Cimon Medical]], [[Norway Health Tech]]
| categories = Norway Health Tech, Startups, Medical Devices, Diagnostics, Intensive Care
| sources = https://www.glucoset.com; https://data.brreg.no/enhetsregisteret/api/enheter/997780922
}}

== About ==

GlucoSet AS is a Norwegian medical device company developing a glucose monitoring sensor for intensive care unit (ICU) patients. Founded in December 2011, the company has 13 employees.

== Technology ==

GlucoSet's sensor is designed to solve a specific clinical problem: accurate glucose monitoring in critically ill ICU patients. The technology:

* Is minimally invasive - accesses through an indwelling arterial catheter without disrupting its current use
* Requires no new catheters - leverages existing arterial access
* Displaces no other equipment - integrates with existing ICU setup
* Is less susceptible to interferences - the arterial access approach may improve measurement reliability compared to subcutaneous sensors

== Clinical Need ==

Glucose control in ICU patients is a significant challenge:

* Both hyperglycemia and hypoglycemia in critically ill patients are associated with increased mortality
* Current glucose monitoring methods (point-of-care, subcutaneous continuous glucose monitoring) have limitations in the ICU setting
* Tight glycemic control in ICUs has been shown to improve outcomes but is difficult to achieve safely

== Market Position ==

GlucoSet targets the ICU glucose monitoring market with a solution designed specifically for the constraints of critical care environments. The company describes the problem as "unsolved," indicating an unmet need.

== References ==
<references/>

[[Category:Norway Health Tech]]
[[Category:Startups]]
[[Category:Medical Devices]]
[[Category:Diagnostics]]
[[Category:Intensive Care]]